Skip to content
Peptigraph home

BPC-157 and CJC-1295 Together: What Is Known

BPC-157 and CJC-1295 taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Gastric pentadecapeptidePCAC voted 8–6 for 503A (Jul 2026)BPC-157BPC-157, an experimental gastric pentadecapeptide, not an approved drug; human evidence is a few small uncontrolled reports, including complete symptom resolution in 10 of 12 patients in a bladder pilot.[7]Healing & recoveryGHRH analogNot FDA approved · research chemicalCJC-1295CJC-1295, a GHRH analog; in healthy adults a single injection produced dose-dependent rises in mean plasma GH of 2- to 10-fold and in IGF-I of 1.5- to 3-fold.[11]Growth hormone
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 7 results, 2 Oct 2026).

Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component

Side by side

Showing 12 of 12 fields where the two differ.

FieldBPC-157CJC-1295
ClassGastric pentadecapeptideGHRH analog
Also calledBPC, body protection compound, Pentadecapeptide BPC 157CJC, mod GRF, GRF 1-29
CategoryHealing & recoveryGrowth hormone
FDA statusPCAC voted 8–6 for 503A (Jul 2026)Not FDA approved · research chemical
PCAC vote, Jul 2026PCAC voted 8–6 for the 503A list (Jul 2026); not finalizedNot on the Jul 2026 agenda
WADAProhibited by WADA (S0)BPC-157 is named in S0 (non-approved substances), prohibited at all times, in and out of competition.Prohibited by WADA (S2.2.4)CJC-1295 is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times.
Anti-doping detection
  • A 2023 method detects BPC-157 and five main metabolites in human urine at very low concentrations.PMID 37959764
  • A 2017 anti-doping lab method detects BPC 157 in urine; the peptide was stable in urine for at least 4 days.PMID 28035768
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
Half-lifeless than 30 minIV and IM (single and repeated) (rat, beagle dog) · Frontiers in pharmacology 2022, PMID 36588717No published half-life foundPubMed search, 11 Oct 2026
Evidence strengthHuman observational evidence, 3 of 4Strongest: Alternative therapies in health and medicine 2025, PMID 40131143Human RCT evidence, 4 of 4Strongest: The Journal of clinical endocrinology and metabolism 2006, PMID 16352683
Human studies we summarised3 human (0 randomized or controlled) of 25 summarised4 human (1 randomized or controlled) of 7 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 10 mg, 20 mg2 mg, 5 mg, 10 mg
Related tools

BPC-157 vs CJC-1295

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

Clinic reports on one side, hormone trials on the other

A BPC-157 bladder-pain pilot reported complete symptom resolution after one treatment in 10 of 12 patients.[7]

CJC-1295 was tested in two randomized, placebo-controlled trials in healthy adults, measuring GH and IGF-I.[11]

After a single CJC-1295 injection, mean GH concentrations rose dose-dependently by 2- to 10-fold for 6 d or more.[11]

Tested together?

The dataset search for this pair found 7 PubMed records, and none is classed as a study of the combination.

Calculated from pubmed query ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("CJC-1295"[tiab] OR CJC1295[tiab]); search date 2026-10-02; records returned 7; records classed as study of the pair 0. Formula: Counts copied from the combinations dataset (web/src/data/combinations.json, key bpc-157__cjc-1295); no arithmetic applied.

A review of performance-peptide use notes uncertainty about product composition, dose and stacking practices in unregulated supply chains.[19]

Safety in the CJC-1295 trials

The healthy-volunteer CJC-1295 trials reported no serious adverse reactions.[11]

Status of each

BPC-157 has no FDA-approved product: the lookup returned no match.[20]

CJC-1295 likewise returned no match in Drugs@FDA.[21]

WADA's prohibited list names CJC-1295 as an example of a GHRH analogue.[2]

Common questions

Can you take BPC-157 and CJC-1295 together?

No study of the two together was classed as relevant; the human BPC-157 and CJC-1295 papers each studied one peptide alone.[11]

BPC-157 vs CJC-1295: which has more human data?

CJC-1295 has randomized trials; the BPC-157 human report cited here is a 12-patient bladder-pain pilot.[7]

Sources

  1. 1FDA gives notice that 12 peptides will be removed from Category 2 (nominations withdrawn)FDA · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3Stable Isotope Labeling-Based Nontargeted Strategy for Characterization of the In Vitro Metabolic Profile of a Novel Doping BPC-157 in Doping Control by UHPLC-HRMS.Molecules (Basel, Switzerland) · 2023PMID 37959764Accessed 2 Oct 2026
  4. 4Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H.Drug testing and analysis · 2017PMID 28035768Accessed 2 Oct 2026
  5. 5Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs.Frontiers in pharmacology · 2022PMID 36588717Accessed 2 Oct 2026
  6. 6Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study.Alternative therapies in health and medicine · 2025PMID 40131143Accessed 2 Oct 2026
  7. 7Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study.Alternative therapies in health and medicine · 2024PMID 39325560Accessed 2 Oct 2026
  8. 8Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study.Joint diseases and related surgery · 2026PMID 42542926Accessed 2 Oct 2026
  9. 9An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  10. 10Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  11. 11Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  12. 12Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.The Journal of clinical endocrinology and metabolism · 2006PMID 17018654Accessed 2 Oct 2026
  13. 13Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.American journal of physiology. Endocrinology and metabolism · 2006PMID 16822960Accessed 2 Oct 2026
  14. 14PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) (33 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  15. 15PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  16. 16PubMed search: ("BPC-157"[tiab] OR BPC157[tiab] OR "body protection compound"[tiab] OR "pentadecapeptide BPC"[tiab]) AND ("CJC-1295"[tiab] OR CJC1295[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17Advisory committee backs 6 of 7 peptides for the 503A listNCPA · 2026ncpa.org
  18. 18PubMed search: ("CJC-1295"[tiab] OR CJC1295[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  19. 19The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration.Frontiers in endocrinology · 2026PMID 42395176Accessed 2 Oct 2026
  20. 20Drugs@FDA (openFDA) search: active ingredient "BPC-157"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  21. 21Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.